Chris Bradley, MS is the Chief Executive Officer and Co-Founder of Matter Bio, a longevity biotechnology company working at the intersection of genome integrity, cancer biology, computational biology, and translational medicine. Trained across neuroscience, cell biology, and computer science, Bradley has built his career around converting complex scientific ideas into companies, products, and clinical programs. At Matter Bio, he leads a team focused on the premise that aging is driven in part by accumulated damage to the genome—mutations, structural variation, epigenetic drift, and other forms of information loss—and that preserving or restoring genomic integrity can open new paths for preventing and treating age-related disease.

Bradley co-founded Matter Bio in 2020 with scientific leaders including George Church Phd , Jan Vijg PhD, Claudia Gravekamp PhD, Alexander Maslov MD, PhD, and Sam Sharifi PhD. The company operates as a platform built around three linked capabilities: detecting genomic information loss, developing approaches to reverse or repair that loss, and eliminating cells too damaged to safely restore, including malignant, clonal, and senescent cells. Matter Bio’s stated goal is to protect cells from damage and remove corrupted cells, with the broader ambition of preventing and treating diseases of aging and potentially extending healthy lifespan.

Bradley’s work at Matter Bio builds on earlier experience as a serial health and biotechnology entrepreneur. Before moving deeply into biotech, Bradley co-founded Mana Health, a health data interoperability company that created technology for unifying patient data from electronic medical records. Mana Health was acquired by Comcast in 2018 and Bradley later helped lead new initiatives and entity formation after the acquisition. That path—from health data infrastructure to oncology and genomic resilience—reflects a recurring theme in his career: building tools that turn biological and medical complexity into actionable systems for researchers, clinicians, and patients.

In addition to his operating roles, Bradley has contributed to academic and policy conversations in health technology and biotechnology. He’s taught at NYU Tandon School of Engineering as adjunct faculty in the Department of Technology Management and Innovation, and is a nationally recognized healthcare innovator who has contributed to conversations at the White House and the Office of the National Coordinator for Health. He has also coauthored peer-reviewed work on age-related somatic mutation burden with leaders in aging biology. Across these roles, Bradley’s professional focus is consistent: translating frontier science into practical interventions that can improve human healthspan, address cancer, and preserve the biological information systems that support long, healthy life.

In his spare time, he loves to sail, hike and travel with his family, and rebuilds antique motorcycle engines into ridable choppers that annoy his neighbors.